Trillium Asset Management LLC Has $2.06 Million Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Trillium Asset Management LLC boosted its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 41.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,947 shares of the company’s stock after acquiring an additional 9,718 shares during the quarter. Trillium Asset Management LLC owned 0.10% of TransMedics Group worth $2,055,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TMDX. Quarry LP increased its position in shares of TransMedics Group by 557.1% during the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after purchasing an additional 312 shares in the last quarter. National Bank of Canada FI raised its stake in shares of TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after acquiring an additional 262 shares during the last quarter. Hager Investment Management Services LLC acquired a new position in shares of TransMedics Group in the 4th quarter worth approximately $33,000. Sachetta LLC bought a new stake in TransMedics Group during the 4th quarter worth approximately $40,000. Finally, AlphaQuest LLC acquired a new stake in TransMedics Group during the 4th quarter valued at $52,000. 99.67% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a report on Wednesday, February 5th. JPMorgan Chase & Co. reissued a “neutral” rating and set a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Piper Sandler reduced their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. Robert W. Baird lowered their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $104.00 price objective on shares of TransMedics Group in a report on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, TransMedics Group currently has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Trading Up 1.9 %

NASDAQ TMDX opened at $70.33 on Thursday. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The company has a market capitalization of $2.37 billion, a PE ratio of 74.82 and a beta of 2.12. The stock has a 50-day simple moving average of $68.19 and a 200 day simple moving average of $91.91.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.